Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
Acquisition Gives The Big Biotech Its First Approved Solid Tumor Drug
Executive Summary
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
You may also be interested in...
AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.